Genzyme, a Sanofi co. (SNY), announced that the Australian Therapeutic Goods Administration or TGA has approved Aubagio or teriflunomide 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis or MS.
The company noted that the TGA's approval of Aubagio was based on safety and efficacy data from the TEMSO or TEriflunomide Multiple Sclerosis Oral trial.
The company said Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system CNS.
Aubagio is marketed in the U.S. and now Australia. Marketing applications for Aubagio are under review by the European Medicines Agency and other regulatory authorities, the compay said.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.